4 Biotechs Expected to See Huge Buying on PowerShares Rebalance
All the major money management firms that run exchange traded funds have to do regular quarterly rebalances to reset their portfolios to the proper allocation levels.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 271Are Mylan Earnings Enough?
ThinkstockMonday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share (EPS) and $2.08 billion in revenue…
Has Biocept Reached an Inflection Point?
Biocept has seen its stock move up over 200% in the past week, only to give back about 20% in Thursday's trading.
5 Health Care Stocks That Are Possible Buyout Candidates
24/7 Wall St. has screened the RBC list of potential takeover candidates for the higher profile and more well-known health care stocks.
Short Sellers Increase Bets Against Biotech as Shares Continue to Rise
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Top UBS Health Care Stocks to Buy for 2015 and Beyond
Bought as a basket, these four companies could offer long-term investors a perfect compliment of stocks covering the health care sector.
Steep Discount on Health Care REIT Secondary Offering
Health Care REIT has priced its underwritten public secondary offering of 17 million shares, but some investors may be wondering if it priced the offering too low.
Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?
ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is compared to the Thomson Reuters…
Biocept Breaks Through With Columbia Study
Biocept has announced that its blood-based diagnostic was used to determine hormonal status of metastatic breast cancer patients in a prospective study at Columbia University in New York.
Is Rigel Getting Enough From Bristol-Meyers?
Rigel Pharmaceuticals and Bristol-Myers Squibb announced Monday morning that they have entered into a collaboration agreement.
Jefferies 4 Top Pharmaceutical Stocks to Buy
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Is Revlimid Becoming a Catch-All Cancer Drug?
Celgene has announced that the FDA expanded the existing indication for Revlimid in conjunction with dexamethasone.
Neurocrine Biosciences Announces New Offering
Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.
Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
Why 1 Analyst Sees Over 50% Upside in Sarepta
Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.